Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 19/20 | 0.62 |
| ▸ | SCTR | P47872 | 1/20 | 0.62 |
| ▸ | TFPI | P10646 | 1/20 | 0.57 |
| ▸ | GCGR | P47871 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29622989 | 0.97 | GLP1R (0.65) | GLP1RSCTRTFPIGCGR | |
| Histatin 5 SCHEMBL31694496 | 0.94 | GLP1R (0.57) | GLP1RSCTRTFPIGCGR | |
| SCHEMBL31690552 | 0.92 | GLP1R (0.61) | GLP1RSCTRTFPIGCGR | |
| SCHEMBL30538628 | 0.92 | TFPI (0.68) | GLP1RSCTRTFPIGCGR | |
| SCHEMBL31683313 | 0.92 | IL23R (0.59) | GLP1RSCTR | |
| SCHEMBL31005069 | 0.91 | TFPI (0.64) | GLP1RSCTRTFPIGCGR | |
| SCHEMBL31690549 | 0.90 | GLP1R (0.61) | GLP1RSCTRTFPI | |
| SCHEMBL30498856 | 0.90 | GLP1R (0.68) | GLP1RSCTR | |
| SCHEMBL29670119 | 0.90 | GLP1R (0.57) | GLP1RSCTRTFPIGCGR | |
| Histatin 3 SCHEMBL31694493 | 0.89 | TFPI (0.63) | GLP1RSCTRTFPIGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4654946-A1 | LIPOSOMAL CONSTRUCT | AC Immune SA (CH) | 2025-12-03 | — | — | EP | disclosed |
| EP-4654990-A1 | ANTI-ABETA VACCINE THERAPY | AC Immune SA (CH) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024156912-A1 | ANTI-ABETA VACCINE THERAPY | AC IMMUNE SA (CH) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024156908-A1 | LIPOSOMAL CONSTRUCT | AC IMMUNE SA (CH) | 2024-08-02 | — | — | WO | disclosed |
| US-20240252507-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-3972633-A1 | ANTI-ABETA VACCINE THERAPY | AC Immune SA (CH) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252507-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | GLP1R 345/4885SCTR 2079/4885TFPI 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.